Shots:

• HilleVax gets an exclusive license for the development and commercialization rights of Takeda’s HIL-214 globally (Ex-Japan). Takeda will hold the commercialization rights of the vaccine in Japan
• Takeda will focus primarily on dengue- COVID-19- pandemic influenza and Zika vaccines. HilleVax will merge Japan development activities into its global development
• HIL-214 is a VLP based vaccine that has completed a P-IIb efficacy study in 4-712 adults- demonstrated clinical POC in preventing mod. to sev. acute gastroenteritis from norovirus infection. The vaccine was well-tolerated

  Ref: GlobeNewswire | Image: Takeda